Skip to content
OpenCapital
Get started

Organon OGN Vytorin — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

United Therapeutics logo
UTHRTotal Tyvaso — Total revenues
$457.5M-1.9%
Gilead Sciences logo
GILDBiktarvy — Total revenues
$3.36B+6.7%
United Therapeutics logo
UTHRTyvaso DPI — Total revenues
$330.3M+9.2%
Jazz Pharmaceuticals logo
JAZZVyxeos — Revenue from Contract with Customer, Excluding Assessed Tax
$26.6M-9.8%
AbbVie logo
ABBVMavyret — Net revenues
$351M+14.7%
AbbVie logo
ABBVVraylar — Net revenues
$905M+18.3%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's vytorin — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's vytorin — revenue?
Organon (OGN) reported vytorin — revenue of $21M in Q1 2026.
How has Organon's vytorin — revenue changed year-over-year?
Organon's vytorin — revenue decreased by 8.7% year-over-year, from $23M to $21M.
What is the long-term trend for Organon's vytorin — revenue?
Over 4 years (2021 to 2025), Organon's vytorin — revenue has grown at a -11.6% compound annual growth rate (CAGR), from $164M to $100M.
What does vytorin — revenue mean?
This metric represents the total gross sales generated from the Vytorin product line within the established medicines portfolio. It reflects the market demand and commercial performance of this specific cardiovascular therapeutic offering. Tracking these revenues helps investors assess the lifecycle stage and contribution of mature pharmaceutical assets to the company's overall top-line results.